Ensartinib for Advanced ALK Rearranged Non-small Cell Lung Cancer
1 Views
administrator
07/14/23
UW Carbone Cancer Center physician Ticiana Leal, MD, explains this phase II study of X-396, now called ensartinib, a novel potent ALK inhibitor in patients with advanced ALK rearranged non-small cell lung cancer.
-
Category
Show more
Facebook Comments
No comments found